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ABSTRACT
Objective: To determine the effectiveness of a provider-
based intervention to improve medication intensification
among patients with diabetes.
Design: Effectiveness cluster-randomised trial. Baseline
and follow-up cross-sections of diabetes physicians’
patients.
Setting: Eleven U.S. Southeastern states, 2006–2008.
Participants: 205 Rural primary care physicians,
95 completed the study.
Intervention: Multicomponent interactive intervention
including web-based continuing medical education (CME),
performance feedback and quality improvement tools.
Primary outcome measures:Medication
intensification, a dose increase of an existing medication
or the addition of a new class of medication for glucose,
blood pressure and lipids control on any of the three most
recent office visits.
Results: Of 364 physicians attempting to register,
102 were randomised to the intervention and 103 to the
control arms; 95 physicians (intervention, n=48; control,
n=47) provided data on their 1182 of their patients at
baseline (intervention, n=715; control, n=467) and 945
patients at follow-up (intervention, n=479; control,
n=466). For A1c control, medication intensification
increased in both groups (intervention, pre 26.4% vs
post 32.6%, p=0.022; control, pre 24.8% vs post 31.1%,
p=0.033) (intervention, adjusted OR (AOR) 1.37; 95% CI
1.06 to 1.76; control, AOR 1.41 (95% CI 1.06 to 1.89));
however, we observed no incremental benefit solely due
to the intervention (group-by-time interaction, p=0.948).
Among patients with the worst glucose control (A1c
>9%), intensification increased in both groups
(intervention, pre 34.8% vs post 62.5%, p=0.002;
control, pre 35.7% vs post 61.4%, p=0.008).
Conclusions: A wide-reach, low-intensity, web-based
interactive multicomponent intervention had no
significant incremental effect on medication
intensification for control of glucose, blood pressure or
lipids for patients with diabetes of physicians practising
in the rural Southeastern USA.
Trial registration: NCT00403091.
INTRODUCTION
Diabetes mellitus is highly prevalent in the
USA.1 Diabetes research has produced clear
evidence that blood glucose, lipid and blood
pressure (BP) control forestall the vascular
complications witnessed with uncontrolled
diabetes. Thus, control of such diabetes care
measures are well-accepted indicators—as
intermediate process outcomes of high quality
of care,2 3 However, diabetes care measures
of their appropriate control lag behind; only
7% of diabetes patients in USA meet the
American Diabetes Association recommenda-
tions for glycated haemoglobin (A1c), BP
and low-density lipoprotein (LDL) control.4
Furthermore, diabetes is more endemic in the
Southern USA and individuals with diabetes in
this area have worse control.5–8 Hence, public
health interventions, which consider distance
barriers in rural setting and aimed at
ARTICLE SUMMARY
Article focus
▪ To determine the effectiveness of a wide-reach
and low-intensity intervention aimed at providers
to improve medication intensification among
patients with diabetes in rural areas.
Key messages
▪ In an effectiveness cluster-randomised trial
among 205 rural physicians in 11 US states
(Southeastern states; 2006–2008; 24 months), a
wide-reach, low-intensity, web-based interactive
multicomponent intervention had no significant
incremental effect on medication intensification
for control of glucose, blood pressure or lipids
for patients with diabetes.
▪ Medication intensification to control glucose
increased in both the intervention and control
groups and it was most significant at very poor
levels of glucose control.
Strengths and limitations of this study
▪ Strenghts include a designed cluster-randomised
trial in a diverse rural area.
▪ Limitations include the self-selection of charts
for data abstraction. A high attrition rate may
have introduced bias.
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improving diabetes control in patients living in rural areas,
are warranted.9–11
The Rural Diabetes Online Care (R-DOC) study was a
rigorously tested cluster-randomised clinical trial compar-
ing a multicomponent physician intervention including
web-based continuous medical education (CME), per-
formance feedback12–14 and quality improvement tools13
to a concurrent control website in rural Southeast USA.15
The primary outcomes were measures of acceptable and
optimal control for A1c, BP and LDL; the secondary out-
comes were process measures (rate of assessment and
group means of A1c, BP and LDL). Despite the non-
signiﬁcant effect attributable to the intervention for any of
the primary outcomes in the R-DOC study, we observed an
absolute increase in the rates of assessment of A1c and
LDL in both study arms (A1c, intervention 30%, control
29%, p<0.001; LDL, intervention 35%, control 38%,
p=0.05).15 However, whether physicians in rural areas
adjust medications to control A1c, BP or LDL has
not been examined in wide-reach, low-intensity interven-
tions9–11 such as the one utilised in the R-DOC study.
Thus, we now report the medication intensiﬁcation
outcomes of the R-DOC study—speciﬁcally, medication
intensiﬁcation to improve overall control of haemoglo-
bin A1c, BP and LDL in the rural Southeastern USA.
Our ﬁndings from the main R-DOC study and this
report have important implications for distant CME pro-
grammes, quality improvement initiatives and implemen-
tation research.
METHODS
Study design and setting
The R-DOC study was a cluster-randomised trial
(ClinicalTrials.gov identiﬁer: NCT00403091). The main
study results—effect of the intervention on diabetes
control—have been published elsewhere.15 Further details
of the study design, web-content, recruitment and reten-
tion processes and patient characteristics have been pub-
lished elsewhere.15–18 Brieﬂy, participants were family,
general and internal medicine physicians located in rural
areas of 11 Southeastern US states (population size
<25 000 habitants). Physicians were enrolled in the study
sequentially from September 2006 to September 2008,
provided informed consent online, and were randomised
to the intervention or control arms using block randomisa-
tion which was concealed to the investigators and statisti-
cians. The unit of randomisation was the physician (and
not a practice); however, for physicians working in a group
practice, only one physician per practice could enrol in
the study. The protocol was approved by the local institu-
tional review boards at The University of Alabama at
Birmingham and Tuscaloosa medical campuses.
Intervention arm description
The website focused on helping physicians to
achieve A1c, BP and LDL control in their diabetic
patients.15 18 Speciﬁcally, the intervention site contained:
(1) challenging cases; (2) individualised diabetes per-
formance feedback reports based on the physician’s own
panel of patients; (3) practice timesavers; (4) practical
goals and guidelines, including guidance for quality
improvement and systems redesign;13 (5) patient
resources; and (6) an area to track and view CME credit.
Intervention arm physicians also received tailored email
reminders about website updated and uncompleted sec-
tions of the website.15
Individualised performance feedback reports were
based on physician’s patients with diabetes. The feedback
reports compared each intervention arm participant’s per-
sonal performance compared to the performance for the
top 10% of other intervention arm participants.12 The
feedback reports consisted of diabetes control (A1c <7%,
systolic BP <130 mmHg, LDL <100 mg/dl), counselling
on diet or exercise and medication intensiﬁcation.15
Control arm description
The control website contained: (1) links to diabetes prac-
tice guidelines and patient education materials; (2) a list
of educational conferences on general medical topics
(updated monthly); (3) an area to track and view their
CME credit and (4) a link to an external medical blog.
Physicians in the control group did not receive perform-
ance feedback reports or electronic communications.
Data sources
All participating physicians provided copies of records of
15 (intervention arm physicians) or 10 (control arm
physicians) of their own consecutively seen patients with
diabetes at baseline and again at follow-up (representing
two cross-sectional views of each physician’s panel of
patients). Since the focus of the intervention was the
physician, we were less interested in speciﬁc patients but
rather each physician’s panel on average. Therefore, two
samples as serial cross-sections would better represent
any change in the physician’s own panel on average.
This method is similar to practice feedback for quality
improvement purposes.19 20 The number of records was
selected to balance rigour and cost (see also sample size
description in the statistical section below).
Patient inclusion criteria were having at least two
ofﬁce visits during the past year and no dialysis, demen-
tia, organ transplantation, HIV/AIDS, terminal illness or
malignancy (except for skin and prostate cancer). Data
abstraction was performed by trained personnel on
blinded records sent to the study centre (or abstracted
on site). Details of data abstracted, quality controls and
physician compensation are published elsewhere.15
Outcomes
In our main study,15 the main outcomes were measures
of acceptable and optimal diabetes control.2 3 The main
outcome for this report is medication intensiﬁcation,
deﬁned as a dose increase of an existing medication or
the addition of a new class of medication for glucose,
blood pressure and lipids control on any of the three
2 Billue KL, Safford MM, Salanitro AH, et al. BMJ Open 2012;2:e000959. doi:10.1136/bmjopen-2012-000959
Medication intensification trial
 group.bmj.com on October 23, 2012 - Published by bmjopen.bmj.comDownloaded from 
most recent ofﬁce visits. Medication intensiﬁcation
equalled the proportion of patients who had a glucose-
lowering medication, antihypertensive medication or
cholesterol-lowering medication added or increased over
the three most recent visits divided by the total number
of patients assessed at baseline or follow-up. As a second-
ary outcome, we also explored medication intensiﬁca-
tion by level of glucose, BP or lipid control.
Statistical approach
We calculated the sample size for the main study
results.15 On the basis of clinically important differences,
the study required 100 physicians per trial arm to detect
a minimum of 0.4% difference in A1c, 6 mm Hg in BP
and 6 mg/dl in LDL for the main outcomes (power
80%, α=0.05, up to 20% dropout) (10 patients per phys-
ician at baseline and at follow-up).15 However, interven-
tion arm physicians were asked to provide 15 patient
records at baseline (and not at follow-up) because of the
need to construct audit and feedback reports as part of
the intervention19 20 for A1c, BP and lipids, reﬂecting
the fact that not all diabetes patients also have hyperten-
sion and hyperlipidaemia. The initial study was not
powered to perform adjusted analysis for the intensiﬁca-
tion outcomes of this report.
All analyses followed the intention-to-treat principle.
The relationship between the main and secondary out-
comes and the effect of the intervention were examined
with generalied linear mixed models (GLMM), account-
ing for clustering of patients within physicians. ORs for
follow-up versus baseline within the two groups were calcu-
lated, adjusting for covariates that differed between base-
line and follow-up patient populations; thus, the covariates
included in these adjusted analyses included race, and
clinical diagnosis of hypertension or depression. GLMM
was implemented by PROC GLIMMIX in SAS and was
adjusted for race, and clinical diagnosis of hypertension or
depression. Thus, the group coefﬁcient represented differ-
ences between the intervention and control groups at
baseline; the time of coefﬁcient represented changes in
the control group over time, thus capturing temporal
trends. Finally, the group-by-time interaction coefﬁcient
represented the difference-of-differences for over-time
change in the intervention versus control group, and was a
direct comparison of over-time change for the interven-
tion versus the control group. A positive OR meant that
the odds of a patient being in control increased more over
time for the intervention versus control group. All analyses
were performed in SAS V.9.2 (Cary, North Carolina, USA).
RESULTS
Recruitment scheme, patient characteristics and web
utilisation
The Consolidated Standards of Reporting Trials diagram
and patients characteristics at baseline and at follow-up
(modiﬁed from a prior publication15) are included in
this report for completeness (ﬁgure 1 and table 1). We
obtained baseline and follow-up data on 95 physicians
(intervention, n=48; control, n=47) and 1182 of their
patients at baseline (intervention, n=715; control,
n=467) and 945 diabetes patients at follow-up (interven-
tion, n=479; control, n=466).
At baseline, intervention group physicians provided
records for fewer African American patients and more
patients with hypertension and depression compared
with control group physicians. Of the 95 physicians,
90 (94.7%) had access to the Internet in the ofﬁce.
Main outcomes: medication intensification
In the adjusted analysis, we saw no signiﬁcant effect
attributable to the intervention in the group-by-time
interaction term for any of the medication intensiﬁca-
tion measures (A1c, BP and LDL; p=0.948, 0.216 and
0.995; respectively).
In the unadjusted analysis, intensiﬁcation of medica-
tions to control A1c increased in both trial arms when
baseline and follow-up data were compared (interven-
tion, 26.4% vs 32.6%, p=0.022; control, 24.8% vs 31.1%,
p=0.033; ﬁgure 2). This was conﬁrmed in the adjusted
analysis (intervention, adjusted OR (AOR) 1.37; 95% CI
1.06 to 1.76; control, AOR 1.41 (95% CI 1.06 to 1.89)).
In the unadjusted analysis, intensiﬁcation of medica-
tions to control BP did not differ for patients cared for
by physicians in either trial arm when comparing base-
line and follow-up data (intervention, 12.3% vs 15.9%,
p=0.080; control, 16.5% vs16.3%, p=0.941; ﬁgure 2).
This ﬁnding was consistent with the adjusted analysis
(intervention, AOR 1.37 (95% CI 0.99 to 1.88); control,
AOR 1.00 (95% CI 0.72 to 1.41)).
In the unadjusted analysis, intensiﬁcation of medica-
tions to control LDL did not differ for patients cared for
by physicians in either trial arm when comparing base-
line and follow-up data (intervention, 10.6% vs 11.3%,
p=0.726; control, 8.1% vs 8.4%, p=0.898; ﬁgure 2). This
ﬁnding was consistent with the adjusted analysis (inter-
vention, AOR 1.05 (95% CI 0.73 to 1.50); control, AOR
1.00, (95% CI 0.65 to 1.53)).
Secondary outcome: medication intensification by strata
In the unadjusted analysis and among patients with
worse glucose control (A1c >9%), intensiﬁcation of med-
ications to control A1c increased in both trial arms
between baseline and follow-up (intervention, pre 34.8%
vs post 62.5%, p=0.002; control, pre 35.7% vs post
61.4%, p=0.008; ﬁgure 3 top panel). For patients whose
last A1c ≥7 to ≤9, we noted an increase in intensiﬁca-
tion between the baseline and follow-up for the inter-
vention group (p=0.005) but no difference in the
control group (p=0.164; ﬁgure 3 top panel). Among
patients with best glucose control (A1c <7%), medica-
tion intensiﬁcation between baseline and follow-up was
similar for both trial arms (intervention, p=0.673;
control, p=0.543; ﬁgure 3 top panel).
In the unadjusted analysis, intensiﬁcation of BP medi-
cation between baseline and follow-up was similar at all
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levels of BP control for both trial arms (ﬁgure 3 middle
panel).
Similarly, in the unadjusted analysis, intensiﬁcation of
lipid-lowering medications between baseline and
follow-up was similar at all levels of LDL control for both
trial arms (ﬁgure 3 bottom panel).
DISCUSSION
In a rigorously designed cluster-randomised trial, a wide-
reach, low-intensity web-based multicomponent interven-
tion for primary care physicians in the rural Southern
USA had no signiﬁcant incremental effect on medica-
tion intensiﬁcation for their diabetes patients’ A1c, BP
or LDL control as compared to a concurrent control
website focusing on diabetes care. However, the absolute
rate of intensiﬁcation of medications to control A1c
increased in both study arms at the end of the study by a
modest amount (∼6%). Although the study was not
designed to perform subgroup analysis, the rate of
intensiﬁcation was greatest among the worst-controlled
patients (A1c >9%) in both study arms (∼25–28%).
Plausible explanations for our ﬁndings include the low
engagement with the intervention, higher-than antici-
pated attrition rate, Hawthorne’s effect or no effect of
the intervention15 18
Medication intensiﬁcation is emerging as a process
measure for quality improvement efforts among patients
with diabetes mellitus; pharmacotherapy intensiﬁcation
is strongly linked to improved A1c, BP and LDL. For
example, in a study of over one million members
with hypertension, hyperlipidaemia and diabetes melli-
tus at Kaiser Permanente Northern California, Selby
et al21 found that a 5% improvement in treatment
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram (a prior version of this figure has been reported,
reproduced with permission15).
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intensiﬁcation led to a 1.0–1.9% improvement in control
for the entire population. However, the association of
treatment intensiﬁcation rates to improved risk factor
control in rural populations has not been examined.
Further evidence and reviews of the importance of medi-
cation intensiﬁcation among patients with diabetes are
available elsewhere22–27.
Trials using medication intensification outcomes
Relatively few studies involving physicians have examined
medication intensiﬁcation as an outcome, none in a
rural setting. Studies have tested the impact of a simu-
lated case-based education with opinion leader feed-
back,28 customised feedback29 and real-time feedback to
patients and their physicians using cell phone software;30
these studies are summarised below.
In a group randomised controlled trial28 of 57 primary
care physicians and 2020 patients in an urban setting, phy-
sicians were randomised to no intervention, a simulated
case-based physician learning intervention, or the same
case-based and leader feedback. Glucose control, mean
A1c value, worsened in the control group by 0.06,
improved in the simulated case-based group by 0.01, and
worsened in the case-based and leader feedback by 0.18.
Among the 907 patients with A1c>7%, medication intensi-
ﬁcation was similar between groups (31.5%, control;
32.6%, case-based; 36.8%, case-based and leader feedback;
p=0.41). Similarly, among the 701 patients with LDL-C
>99 mg/dl, medication intensiﬁcation was similar between
Table 1 Characteristics of diabetes patients of 95 physicians randomised to intervention (n=48) or control (n=47) who
completed follow-up
Patient characteristic
Baseline Follow-up
Intervention
(n=715)
Control
(n=467)
Total
(n=1182)
Intervention
(n=479)
Control
(n=466)
Total
(n=945)
Age (years) 58.7 (13.59) 60.6 (13.79) 59.4 (13.70) 61.3 (13.42) 60.5 (12.71) 60.9 (13.09)
Gender, female 360 (51.1%) 230 (49.5%) 590 (50.5%) 260 (54.5%) 252 (54.4%) 512 (54.5%)
Race, African American 97 (13.9%) 99 (21.3%) 196 (16.9%) 102 (21.4%) 143 (30.9%) 245 (26.1%)
Obesity* 274 (38.3%) 193 (41.3%) 467 (39.5%) 97 (20.3%) 75 (16.1%) 172 (18.2%)
Smoker, current 85 (12.5%) 55 (12.3%) 140 (12.4%) 63 (13.8%) 53 (13.0%) 116 (13.4%)
No self-testing 168 (33.6%) 114 (36.3%) 282 (34.6%) 189 (41.4%) 183 (44.7%) 372 (43.0%)
Non-adherence to
appointments
75 (11.0%) 54 (12.0%) 129 (11.4%) 10 (2.2%) 23 (5.6%) 33 (3.8%)
Insurance, Medicaid 65 (9.1%) 51 (10.9%) 116 (9.8%) 66 (13.8%) 58 (12.4%) 124 (13.1%)
Comorbidities
Diabetes complications† 147 (20.6%) 110 (23.6%) 257 (21.7%) 156 (32.6%) 134 (28.8%) 290 (30.7%)
Insulin use 103 (14.4%) 66 (14.1%) 169 (14.3%) 84 (17.5%) 68 (14.6%) 152 (16.1%)
Hypertension 473 (66.2%) 304 (65.1%) 777 (65.7%) 327 (68.3%) 283 (60.7%) 610 (64.6%)
Hyperlipidaemia 110 (15.4%) 85 (18.2%) 195 (16.5%) 11 (2.30%) 17 (3.7%) 28 (3.0%)
Peripheral vascular disease 47 (6.6%) 31 (6.6%) 78 (6.6%) 41 (8.6%) 35 (7.5%) 76 (8.0%)
Coronary artery disease 135 (18.9%) 83 (17.8%) 218 (18.4%) 111 (23.2%) 95 (20.4%) 206 (21.8%)
Vascular intervention‡ 60 (8.4%) 47 (10.1%) 107 (9.1%) 36 (7.5%) 40 (8.6%) 76 (8.0%)
Depression 105 (14.7%) 61 (13.1%) 166 (14.0%) 84 (17.5%) 60 (12.9%) 144 (15.2%)
A prior version of this table has been reported (reproduced with permission).15
Values are mean (SD) or n (%).
*Obesity: body mass index ≥ 30 kg/m2 or clinical diagnosis.
†Diabetes complications: retinopathy, neuropathy or nephropathy.
‡Vascular intervention: coronary artery bypass grafting, stent, percutaneous coronary angioplasty.
Figure 2 Medication
intensification for haemoglobin
A1c (%), blood pressure (BP,
mm Hg) and cholesterol
(low-density lipoprotein (LDL),
mg/dl) control for intervention
(n=48) or control (n=47)
physicians, at baseline (pre,
n=1182 patients) and follow-up
(post, n=945 patients). See text
for definitions of medication
intensification.
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groups (20.8%, control; 24.2%, case-based; 21.8%, case-
based and leader feedback; p=0.66). Finally, among the
949 patients with BP values >130/mmHg, medication
intensiﬁcation was similar between groups (27.3%,
control; 24.7%, case-based; 28.2%, case-based and leader
feedback; p=0.61). Medication intensiﬁcation was deﬁned
by the initiation or titration in 12 months after the inter-
vention for all patients with goals above target (A1c>=7%,
LDL-C >=100 mg/dl, BP>130/80 mmHg); insulin titra-
tion was excluded from the outcome. The attrition rate
was 33% (38/59 physicians). Our case scenarios took less
than 10 min to complete as compared with the ones in
this study (over 60 min each).28 Perhaps striking a balance
between more ‘intense’ cases to increase physician engage-
ment and providing feedback information may lead to the
improvement in medication intensiﬁcation. Finally, the
medication intensiﬁcation rates deﬁnitions were different
from ones used in our study; hence, they cannot be
compared.
In a randomised trial of 3703 patients with diabetes
and their 123 physicians, participants were randomised to
receive customised feedback of clinical information in
four groups: patient only, physician only, both the patient
and physician, or neither one.29 At 12 months, interven-
tions had no effect on A1c test ordering, medication
intensiﬁcation or improvement in A1c or LDL control.
Medication intensiﬁcation was deﬁned as in the above
study.28 In our study, we included customised feedback as
one of the many components of the intervention.
In a pilot-controlled trial,30 30 patients with diabetes
were randomised to an intervention group consisting of
cell phone-based software which provided real-time feed-
back on glucose levels, medication regimens and sug-
gested treatment algorithms or a control group.
Intervention providers received patients’ logbooks and
suggested treatment plans to reach A1c<6.5%. During
the 3 months of the study, the A1c levels decreased
among patients in the intervention as compared with
the control group (by 2.0% vs 0.7%; respectively); medi-
cations were changed or intensiﬁed in 84% in the inter-
vention group as compared with 23% patients in the
control group (p<0.002). The operational deﬁnition for
Figure 3 Medication
intensification for strata of
haemogloblin A1c (%), blood
pressure (BP, mm Hg) and
cholesterol (low-density
lipoprotein (LDL), mg/dl) control.
See text for definitions of
medication intensification.
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medication intensiﬁcation in this study was not reported.
Cell phone technology provides the opportunity for
wide reach approach. In our study, physicians and not
their patients received the customised feedback on their
group of patients.
Limitations
Our study had limitations.15 First, physicians themselves
provided the records of consecutively seen patients;
although selection bias was a possibility, the wide range
of A1c, BP and LDL values suggests that not only well-
controlled patients were selected. Second, the high attri-
tion, 95 of the 205 randomised physicians provided base-
line and follow-up data, may have introduced biases. By
design, to test a purely online intervention, we chose not
to enhance retention activities as typically seen in rando-
mised clinical trials and focused on several aspects of
provider-based implementation tools.13 Although a com-
prehensive analysis would have been enlightening, we
did not perform a systematic examination of this nega-
tive trial, or how such intervention might work it were
effective. We worried that studying the study while being
conducted would have introduced another variable.
Implications
A framework has been proposed to evaluate the public
health impact of interventions.9–11 The components of
the framework include reach (‘How many participate?’),
effectiveness (‘Does it work in usual settings?’), adoption
(‘How many use it?’), implementation (‘Is it used as
intended?’) and maintenance (‘Is it sustained over
time?’) (RE-AIM). In this study, using a wide-reach
approach, we examined the effectiveness of a potential
public health intervention. Effective interventions may
be limited by their low-reach, speciﬁcity to fewer settings,
expense and limited sustainability—thus limiting their
generalisability. Testing less intensive interventions with
wider reach in rural settings has been advocated in
public health interventions.11 Finding effective strategies
to accomplish continuing professional development for
physicians practising in remote locations is also an
important objective.31 In contrast, higher-intensity inter-
ventions in rural and community settings have shown
promising results.32–36
CONCLUSION
In conclusion, a wide-reach, low-intensity, web-based
interactive multicomponent intervention had no signiﬁ-
cant incremental effect on medication intensiﬁcation for
control of glucose, BP or lipids for patients with diabetes
of physicians practising in the rural Southeastern USA.
Despite low engagement in the web-based programme,
intensiﬁcation measures improved in both arms of the
study. Our study raises important issues for wide-reach,
low-intensity CME programmes that seek to improve
patient outcomes.
Author affiliations
1The University of Alabama at Birmingham, Birmingham, Alabama, USA
2VA Tennessee Valley Healthcare Geriatric Research, Education, Clinical Center
(GRECC) and Vanderbilt University, Nashville, Tennessee, USA
3Bedford Veterans Affairs Medical Center, Beford, Massachusetts, USA
4The University of Massachusetts Medical School, Worcester, Massachusetts,
USA
5Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA
6Birmingham VAMC,Veterans Affairs National Quality Scholars Program,
Birmingham, Alabama, USA
Contributors KB wrote the article and contributed in the interpretation of the
findings. YK conducted the analyses and contributed to the writing of the
Methods and Results sections. MMS, AHS, TKH, WC, JJA, CAE contributed to
the conceptualisation of the project, the interpretation of the findings and to
the writing of all sections of the article. JJA conceived and supervised the
study. All authors contributed to reviewing drafts of the article.
Funding This work was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) 5R18DK065001 to JJA. AHS and CAE
were supported by the Veterans Affairs National Quality Scholars Program.
The sponsors had no role in the design and conduct of the study; collection,
management, analysis and interpretation of the data; and preparation, review
or approval of the manuscript.
Competing interests The opinions expressed in this article are those of the
authors alone and do not reflect the views of the Department of Veterans
Affairs.
Ethics approval Institutional review boards at The University of Alabama at
Birmingham and Tuscaloosa medical campuses.
Provenance and peer review Not commissioned; externally peer reviewed
Data sharing statement No additional data are available.
REFERENCES
1. Centers for Disease Control and Prevention. National diabetes fact
sheet: general information and national estimates on diabetes in
the United States, 2007. Atlanta, GA: U.S. Department of Health
and Human Services, Centers for Disease Control and Prevention,
2008.
2. American Diabetes Association. Standards of medical care in
diabetes–2006. Diabetes Care 2006;29(Suppl 1):S4–42.
3. National Committee for Quality Assurance. Comprehensive diabetes
care. HEDIS 2009 volume 2 technical update, 2008.
4. Weitzman S, Greenfield S, Billimek J, et al. Improving combined
diabetes outcomes by adding a simple patient intervention to
physician feedback: a cluster randomized trial. Isr Med Assoc J
2009;11:719–24.
5. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care
delivered to Medicare beneficiaries: a profile at state and national
levels. JAMA 2000;284:1670–6.
6. Weingarten JP Jr, Brittman S, Hu W, et al. The state of diabetes
care provided to Medicare beneficiaries living in rural America.
J Rural Health 2006;22:351–8.
7. Andrus MR, Kelley KW, Murphey LM, et al. A comparison of
diabetes care in rural and urban medical clinics in Alabama.
J Community Health 2004;29:29–44.
8. Krishna S, Gillespie KN, McBride TM. Diabetes burden and access
to preventive care in the rural United States. J Rural Health
2010;26:3–11.
9. Glasgow RE, Emmons KM. How can we increase translation of
research into practice? Types of evidence needed. Annu Rev Public
Health 2007;28:413–33.
10. Glasgow RE, Klesges LM, Dzewaltowski DA, et al. Evaluating the
impact of health promotion programs: using the RE-AIM framework
to form summary measures for decision making involving complex
issues. Health Educ Res 2006;21:688–94.
11. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health
impact of health promotion interventions: the RE-AIM framework.
Am J Public Health 1999;89:1322–7.
12. Weissman NW, Allison JJ, Kiefe CI, et al. Achievable benchmarks of
care: the ABCs of benchmarking. J Eval Clin Pract 1999;5:269–81.
13. Salanitro AS, Estrada CA, Allison JJ. Implementation research:
beyond the traditional randomized controlled trial. In: Glasser S, ed.
Billue KL, Safford MM, Salanitro AH, et al. BMJ Open 2012;2:e000959. doi:10.1136/bmjopen-2012-000959 7
Medication intensification trial
 group.bmj.com on October 23, 2012 - Published by bmjopen.bmj.comDownloaded from 
Essentials of clinical research. New York, NY: Springer Science,
2008:217–44.
14. Kiefe CI, Allison JJ, Williams OD, et al. Improving quality
improvement using achievable benchmarks for physician feedback:
a randomized controlled trial. JAMA 2001;285:2871–9.
15. Estrada CA, Safford MM, Salanitro AH, et al. A web-based diabetes
intervention for physician: a cluster-randomized effectiveness trial.
Int J Qual Health Care 2011;23:682–9.
16. Foster PP, Williams JH, Estrada CA, et al. Recruitment of rural
physicians in a diabetes internet intervention study: overcoming
challenges and barriers. J Natl Med Assoc 2010;102:101–7.
17. Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying
medications: differentiating ‘clinical inertia’ from appropriate care.
J Gen Intern Med 2007;22:1648–55.
18. Crenshaw K, Curry W, Salanitro AH, et al. Is physician engagement
with Web-based CME associated with patients’ baseline hemoglobin
A1c levels? The Rural Diabetes Online Care study. Acad Med
2010;85:1511–17.
19. Allison JJ, Calhoun JW, Wall TC, et al. Optimal reporting of health
care process measures: inferential statistics as help or hindrance?
Manag Care Q 2000;8:1–10.
20. Holmboe ES, Meehan TP, Lynn L, et al. Promoting physicians’
self-assessment and quality improvement: the ABIM diabetes practice
improvement module. J Contin Educ Health Prof 2006;26:109–19.
21. Selby JV, Uratsu CS, Fireman B, et al. Treatment intensification and
risk factor control: toward more clinically relevant quality measures.
Med Care 2009;47:395–402.
22. Zikmund-Fisher BJ, Hofer TP, Klamerus ML, et al. First things first:
difficulty with current medications is associated with patient
willingness to add new ones. Patient 2009;2:221–31.
23. Bebb C, Kendrick D, Coupland C, et al. A cluster randomised
controlled trial of the effect of a treatment algorithm for hypertension
in patients with type 2 diabetes. Br J Gen Pract 2007;57:136–43.
24. Carter BL, Bergus GR, Dawson JD, et al. A cluster randomized
trial to evaluate physician/pharmacist collaboration to improve
blood pressure control. J Clin Hypertens (Greenwich)
2008;10:260–71.
25. Grant R, Adams AS, Trinacty CM, et al. Relationship between
patient medication adherence and subsequent clinical inertia in type
2 diabetes glycemic management. Diabetes Care 2007;30:807–12.
26. Rodondi N, Peng T, Karter AJ, et al. Therapy modifications in
response to poorly controlled hypertension, dyslipidemia, and
diabetes mellitus. Ann Intern Med 2006;144:475–84.
27. Heisler M, Hogan MM, Hofer TP, et al. When more is not better:
treatment intensification among hypertensive patients with poor
medication adherence. Circulation 2008;117:2884–92.
28. O’Connor PJ, Sperl-Hillen JM, Johnson PE, et al. Simulated
physician learning intervention to improve safety and quality of
diabetes care: a randomized trial. Diabetes Care 2009;
32:585–90.
29. O’Connor PJ, Sperl-Hillen J, Johnson PE, et al. Customized
feedback to patients and providers failed to improve safety or
quality of diabetes care: a randomized trial. Diabetes Care
2009;32:1158–63.
30. Quinn CC, Clough SS, Minor JM, et al. WellDoc mobile diabetes
management randomized controlled trial: change in clinical and
behavioral outcomes and patient and physician satisfaction.
Diabetes Technol Ther 2008;10:160–8.
31. Curran V, Rourke L, Snow P. A framework for enhancing continuing
medical education for rural physicians: a summary of the literature.
Med Teach 2010;32:e501–8.
32. Maclean CD, Gagnon M, Callas P, et al. The Vermont diabetes
information system: a cluster randomized trial of a population based
decision support system. J Gen Intern Med 2009;24:1303–10.
33. Khan S, Maclean CD, Littenberg B. The effect of the Vermont
Diabetes Information System on inpatient and emergency room
use: results from a randomized trial. Health Outcomes Res Med
2010;1:e61–6.
34. Beem SE, Machala M, Holman C, et al. Aiming at ‘de feet’ and
diabetes: a rural model to increase annual foot examinations. Am J
Public Health 2004;94:1664–6.
35. Mayer-Davis EJ, D’Antonio AM, Smith SM, et al. Pounds off with
empowerment (POWER): a clinical trial of weight management
strategies for black and white adults with diabetes who live in
medically underserved rural communities. Am J Public Health
2004;94:1736–42.
36. Spencer MS, Rosland AM, Kieffer EC, et al. Effectiveness of a
community health worker intervention among African American and
Latino adults with type 2 diabetes: a randomized controlled trial. Am
J Public Health 2011;101:2253–60.
8 Billue KL, Safford MM, Salanitro AH, et al. BMJ Open 2012;2:e000959. doi:10.1136/bmjopen-2012-000959
Medication intensification trial
 group.bmj.com on October 23, 2012 - Published by bmjopen.bmj.comDownloaded from 
doi: 10.1136/bmjopen-2012-000959
 2012 2: BMJ Open
 
Katherine L Billue, Monika M Safford, Amanda H Salanitro, et al.
 
effectiveness trial
rural primary care: a cluster-randomised 
Medication intensification in diabetes in
 http://bmjopen.bmj.com/content/2/5/e000959.full.html
Updated information and services can be found at: 
These include:
References
 http://bmjopen.bmj.com/content/2/5/e000959.full.html#ref-list-1
This article cites 33 articles, 7 of which can be accessed free at:
Open Access
http://creativecommons.org/licenses/by-nc/2.0/legalcode.
http://creativecommons.org/licenses/by-nc/2.0/ and 
compliance with the license. See:
work is properly cited, the use is non commercial and is otherwise in 
use, distribution, and reproduction in any medium, provided the original
Creative Commons Attribution Non-commercial License, which permits 
This is an open-access article distributed under the terms of the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (50 articles)General practice / Family practice   
 (49 articles)Evidence based practice   
 (24 articles)Diabetes   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on October 23, 2012 - Published by bmjopen.bmj.comDownloaded from 
